Journal List > J Korean Endocr Soc > v.23(1) > 1003428

Park: Naloxone Increases the Anorexic Effect of Melanocortin II

References

1. Drazen DL, Woods SC. Peripheral signals in the control of satiety and hunger. Curr Opin Clin Nutr Metab Care. 2003. 6:621–629.
2. Druce MR, Small CJ, Bloom SR. Minireview: Gut peptides regulating satiety. Endocrinology. 2004. 145:2660–2665.
3. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science. 2005. 307:1909–1914.
4. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000. 404:661–671.
5. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004. 116:337–350.
6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994. 372:425–432.
7. Porte D Jr, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002. 60:S20–S29.
8. Shek EW, Scarpace PJ. Resistance to the anorexic and thermogenic effects of centrally administrated leptin in obese aged rats. Regul Pept. 2000. 92:65–71.
9. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role ofleptin in the neuroendocrine response to fasting. Nature. 1996. 382:250–252.
10. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995. 269:543–546.
11. Van HM, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest. 1997. 99:385–390.
12. Widdowson PS, Upton R, Buckingham R, Arch J, Williams G. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes. 1997. 46:1782–1785.
13. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 2004. 279:34733–34740.
14. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996. 348:159–161.
15. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA. 1997. 94:8878–8883.
16. Jonsson L, Skarphedinsson JO, Skuladottir GV, Atlason PT, Eiriksdottir VH, Franzson L, Schioth HB. Melanocortin receptor agonist transiently increases oxygen consumption in rats. Neuroreport. 2001. 12:3703–3708.
17. Kim YW, Choi DW, Park YH, Huh JY, Won KC, Choi KH, Park SY, Kim JY, Lee SK. Leptin-like effects of MTII are augmented in MSG-obese rats. Regul Pept. 2005. 127:63–70.
18. Brugman S, Clegg DJ, Woods SC, Seeley RJ. Combined blockade of both micro - and kappa-opioid receptors prevents the acute orexigenic action of Agouti-related protein. Endocrinology. 2002. 143:4265–4270.
19. Bae JH, Park YH, Kim SH, Park SY, Kim JY, Son JY, Huh JY, Won KC, Kim YW. Naloxone Increases the Anorexic Effect of MTII in OLETF Rats. J Kor Endocr Soc. 2008. 23:18–26.
20. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord. 2002. 26:Suppl 4. S29–S33.
21. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab. 2002. 16:717–742.
22. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000. 404:672–677.
TOOLS
Similar articles